STRO
SUTRO BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$15.34
−0.90%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$1.66
- Revenue estimate
- $13.6M
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$2.33
- EPS estimate
- -$2.19
- Revenue actual
- $9.8M
- Revenue estimate
- $12.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -26.5%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $47
- PT range
- $34 – $60
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$2.19 | -$2.33 | Miss -6.39% | $9.8M |
| May 14, 2026 | -$2.32 | -$2.94 | Miss -26.72% | $14.5M |
| Mar 26, 2026 | -$4.66 | -$5.29 | Miss -13.52% | $11.7M |
| Nov 6, 2025 | -$4.20 | -$6.70 | Miss -59.52% | $9.7M |
| Aug 7, 2025 | -$0.39 | -$0.14 | Beat 64.10% | $63.7M |
| May 8, 2025 | -$0.63 | -$0.91 | Miss -44.44% | $17.4M |
| Mar 13, 2025 | -$0.86 | -$0.89 | Miss -3.49% | $14.8M |
| Aug 13, 2024 | -$0.76 | -$0.59 | Beat 22.37% | $25.7M |
| Nov 13, 2023 | -$0.76 | -$0.81 | Miss -6.58% | $16.9M |
| Aug 10, 2023 | -$0.73 | -$0.64 | Beat 12.33% | $10.4M |
| May 15, 2023 | -$0.83 | -$0.76 | Beat 8.43% | $12.7M |
| Feb 28, 2022 | -$0.67 | -$0.83 | Miss -23.88% | $10.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026